The agouti-related protein is a powerful orexigenic peptide. A rare mutation, þ 79G4A, was identified in its minimal promoter in two white carriers. Comparison of the 45-year-old male proband, who was also a carrier of the common Ala67Thr polymorphism, with an age-and weight-matching wild-type population showed marginal differences for resting metabolic rate (RMR) and body mass index. The second carrier however was an obese 57-year-old female with reduced RMR. Functional analysis in hypothalamus-and periphery-derived cell lines showed reduced promoter activity for the þ 79A allele in the adrenocortical cells only, suggesting that it could affect the peripheral expression levels of AgRP. The þ 79G4A mutation could predispose to body weight gain (as suggested by the phenotype of the second carrier), but it could only affect the proband at an older age as he may be protected by the Ala67Thr polymorphism that is associated with resistance to late-onset fatness.
Introduction
Agouti-related protein (AgRP) is a powerful orexigenic peptide binding antagonistically to melanocortin receptors in the hypothalamus. The ubiquitous overexpression of AgRP in transgenic mice results in obesity (Graham et al., 1997) , whereas deletion of the gene has no phenotype (Qian et al., 2002) or displays an age-dependent leanness (Wortley et al., 2005) . Human AgRP mRNA is found in two isoforms: the longer transcript comprising the 5 0 non-coding exon in the hypothalamus and the shorter one found in peripheral tissues but missing the 5 0 non-coding exon (Ollmann et al., 1997) . Although only a few studies have focused on peripheral AgRP action, these studies highlight the potential for circulating or locally produced AgRP to influence peripheral tissues. The adrenal gland is indeed the site with the highest AgRP expression where it is also upregulated by fasting . A study in a Japanese cohort showed a direct correlation between high AgRP plasma levels and obesity (Katsuki et al., 2001 ), but two recent reports showed a negative correlation between AgRP plasma levels and body mass index (BMI) (Gavrila et al., 2005; Moriya et al., 2006) .
Mutation screening in humans has revealed several functional single-nucleotide polymorphisms (SNPs) in AgRP that were associated with phenotypes of leanness. Two SNPs in the 5 0 -UTR (À3019G4A and À38C4T) have been reported in black subjects, but not in white subjects. SNP À3019G4A was in complete linkage disequilibrium with SNP À38C4T, but the two linked alleles had opposite effects on promoter activity with the net effect likely being determined by the À38C4T SNP because of its position in a region with 1000-fold higher promoter activity . The T allele of the À38C4T SNP has been associated with leanness in Sierra Leonean black subjects and reduced fatness in black subjects of the HERITAGE Family Study (Argyropoulos et al., 2003) . In addition, the T/T genotype was associated with resistance to developing type 2 diabetes mellitus in Sierra Leoneans ) a finding that was confirmed by an independent study in a different cohort of West Africans (Bonilla et al., 2006) . An SNP in the coding region that changed the alanine at position 67 to a threonine (Ala67Thr) was found in white subjects only ) and was associated with anorexia nervosa (Vink et al., 2001) . Subsequent studies showed that Ala67Thr heterozygotes were resistant to late-onset fatness whereas the Ala67Ala homozygotes had higher BMI and increased body fatness (Argyropoulos et al., 2002) .
Promoter SNPs in AgRP have so far been found in black subjects only. Here, we report a novel heterozygous mutation at position þ 79 changing the guanine to an adenine ( þ 79G4A) in the promoter of AgRP of two white individuals. Functional studies in hypothalamus-and peripheryderived cell lines showed reduction in promoter activity by the þ 79A allele, but only in an adrenocortical cell line. The functional significance of this rare mutation is discussed in conjunction with its functional properties and the phenotypes of the two carriers.
Materials and methods

Mutation screening and genotyping
Mutation screening of the minimal promoter of AgRP and genotyping were carried out as described previously (Sozen et al., 2001; Argyropoulos et al., 2003) . A cohort of 95 individuals comprising blacks (N ¼ 47) and whites (N ¼ 48) was screened for the presence of mutations in AgRP. One individual was found with the þ 79G4A mutation. Nucleotide numbering was based on the published sequence of the human AgRP gene promoter ) (GenBank Accession Number: AF314194). Confirmation of the heterozygous þ 79G4A mutation was performed by bidirectional sequencing on an ABI 373 Sequencer (Applied Biosystems, Foster City, CA, USA). Further mutation screening was performed in two additional cohorts consisting of 356 and 500 subjects, respectively, each consisting of blacks and whites (25:75%, respectively). A fourth cohort of 13 age-and BMI-matched individuals was compiled from existing databases with available data for energy expenditure. These studies were approved by the Institutional Review Board of the Pennington Biomedical Research Foundation. Mutation scoring was performed by polymerase chain reaction using the same primers that were used to clone the mutant alleles into the pGL3-basic luciferase vector (below) and restriction digestion of the amplicons with the Hpy188 III restriction enzyme, as prescribed by the manufacturer (New England Biolabs, Beverly, MA, USA).
Proband characteristics
The compound heterozygote ( þ 79G4A and Ala67Thr) proband was a 45-year-old male Caucasian of Mediterranean origin, with a BMI of 25.3 kg/m 2 . He had no self-reported or diagnosed eating disorders. He has been on antihypertension (lisinopril, 10 mg/day) and antihyperlipidemia (lipitor, 20 mg/day) medication for 5 years. It is worth noting that his high-density lipoprotein was a high 87 mg/dl. His mother had type 2 diabetes mellitus and had undergone triple bypass at the age of 66 years. She was overweight (BMI, 29.9 kg/m 2 ) and also suffered from hyperlipidemia. The father had no reported eating disorders and his BMI was 27.3 kg/m 2 .
Luciferase expression constructs Luciferase expression constructs, to evaluate the effects of the two genotypes (G/G and A/A) of the þ 79G4A mutation were made as described previously . Specifically, DNA from the heterozygous individual was amplified by PCR using the following primers: forward: 5 0 -AA TGC GCT AGC ATG GTT CTA GCC CTG CTC AGC-3 0 , reverse: 5 0 -AA TTA CCC GGG AAC CTG AGG ACT CAC CTC TGC-3 0 . Amplicons were directionally cloned into the pGL3-basic luciferase vector (Promega, Madison, WI, USA) using restriction endonucleases recognition sites added to the primers (Nhe I on the forward and Xma I on the reverse primers). The first nucleotide of the forward primer corresponded to position À18 and the last nucleotide on the reverse primer to position þ 312 of the DNA sequence with GenBank Accession Number AF314194. Confirmation of integrity of the DNA and the presence of the two alleles was confirmed by bidirectional sequencing with the following primers: forward: 5 0 -ATG GTT CTA GCC CTG CTC AGC-3 0 , reverse: 5 0 -AAC CTG AGG ACT CAC CTC TGC-3 0 .
Cell culture
Cell culture was carried out under standard conditions in a humidified incubator at 371C and 5% CO 2 as described previously Bai et al., 2004; Charbonneau et al., 2004) . Cells were transfected in quadruplicates for each construct, and each quadruplicate experiment was performed at least twice in each cell line. Each quadruplicate experiment was averaged, and the standard deviation was calculated. The Student's t-test was used to evaluate for statistical significance between the effects of each genotype on promoter (luciferase) activity. All luciferase activity measurements were normalized to renilla values that were measured with the same luminometer in each sample.
Resting metabolic rate
Resting metabolic rate (RMR) was measured as described previously (de Jonge et al., 2001 ) and according to the Harris Benedict equation (Garrel et al., 1996) . All participating individuals signed informed consent forms, and the study was conducted according to the Institutional Review Board of the Pennington Biomedical Research Center.
Results and discussion
We report here a rare heterozygous mutation in the minimal promoter of AgRP, þ 79G4A, in two white individuals (Figure 1 ). The first individual found with the mutation was termed the 'proband'. He was a 45-year-old white male of Mediterranean origin with a BMI of 25.3 kg/m 2 . He was also heterozygous for the more common Ala67Thr polymorphism that has been associated with resistance to lateonset fatness in white subjects (Argyropoulos et al., 2002) . The second individual with the mutation (but 'wild type' for the Ala67Thr SNP) was an obese 57-year-old women with significantly reduced RMR (Table 1) . Functional analysis of the mutation was carried out in three different cell lines to determine its impact on promoter activity in different cellular environments. The mutation was found in a region that has been shown to have significant promoter activity . The mutant allele, þ 79A, resulted in significant downregulation of promoter activity in the human NCI-h295R adrenocortical cells that was paralleled by the same trend in the Chinese hamster ovary cells (Figure 2) . The effect of the mutant allele, however, was in the opposite direction in the mouse hypothalamus GT1-7 cells, but not at significant Figure 1 Electropherograms representing the three states of the mutation indicated by the arrows is as follows: (a) genomic DNA from the proband carrying the þ 79G4A mutation, (b) plasmid DNA after cloning amplicons from the proband into the pGL3-basic vector showing the þ 79G and (c) the þ 79A alleles. levels ( Figure 2a ). The significance of this discrepancy remains uncertain, but if we were to take into account only the statistically significant data, the mutation could lead to a decrease of peripherally expressed AgRP. The functional significance of peripherally expressed AgRP also remains uncertain at this point, but it has been shown that peripherally administered AgRP does not cross readily the blood-brain barrier, but infiltrates various organs in a fasting-dependent manner with high preference for the liver and the adrenal gland (Pan et al., 2005) . A knockdown experiment by injection of small interfering RNA in the hypothalamus showed a reduction in endogenous AgRP and an increase in metabolic rate (Makimura et al., 2002) . We, therefore, compared the RMR) of the proband against the second carrier and a cohort of 13 wild-type ageand BMI-matched individuals ( Table 1 ). The second carrier (and marginally the proband) had reduced RMR compared to the mean of the wild-type individuals, which raises the possibility that the rare SNP might be associated with reduced RMR and increased BMI. This association would require that reduced AgRP in the periphery but not in the hypothalamus (as suggested by the functional analysis of the mutation) is associated with reduced RMR and increased BMI. This possibility is supported by recent data showing that reduced peripheral levels of AgRP are associated with higher BMI (Gavrila et al., 2005; Moriya et al., 2006) . In the absence of data for circulating AgRP in the two carriers of the mutation, however, it is inappropriate to speculate further on this possibility.
NCI-h295R
It is concluded that the þ 79G4A mutation could predispose to reduced RMR and increased fatness, according to the phenotype of the 57-year-old female carrier. The 45-year-old proband, on the other hand, might become obese at an older age, or perhaps not at all, as he may be protected by the Ala67Thr SNP that is associated with resistance to late onset fatness (Argyropoulos et al., 2002) .
